Literature DB >> 20619139

[Effects of moxibustion at head-points on levels of somatostatin and arginine vasopressin from cerebrospinal fluid in patients with vascular dementia: a randomized controlled trial].

Pin Wang1, Jun Yang, Gang Liu, Hao Chen, Fan Yang.   

Abstract

BACKGROUND: There are obvious changes in neuropeptides from plasma and cerebrospinal fluid in patients with vascular dementia (VaD), and regulating the levels of neuropeptides is a key for prevention and treatment of VaD.
OBJECTIVE: To observe the clinical efficacy of moxibustion at head-points in treatment of vascular dementia (VaD), and assess its effects on memory-related neuropeptides. DESIGN, SETTING, PARTICIPANTS AND
INTERVENTIONS: A total of 65 VaD patients from Acupuncture Hospital, Anhui University of Traditional Chinese Medicine, were randomly divided into moxibustion group (33 cases) and Western medicine group (32 cases). Patients in the moxibustion group were treated with indirect moxibustion with common monkshood cake for 20 min. Patients in the Western medicine group were orally administered piracetam tablets, 0.8 g for three times a day. One treatment course was 4 weeks, and they were treated for 4 treatment courses. MAIN OUTCOME MEASURES: The scores of Hasegawa's Dementia Scale (HDS), Mini-Mental State Examination (MMSE), and Activity of Daily Living Scale (ADL), as well as the levels of learning and memory-related neuropeptides from cerebrospinal fluid such as somatostatin (SS) and arginine vasopressin (AVP) were measured before and after treatment in the two groups.
RESULTS: Total response rate was significantly higher in the moxibustion group than in the Western medicine group (P<0.01). There were significant differences in scores of HDS, MMSE and ADL between before and after treatment in the two groups(P<0.05 or P<0.01). After treatment, the scores of HDS, MMSE and ADL in the moxibustion group were more improved as compared with those in the Western medicine group (P<0.05 or P<0.01). The levels of SS and AVP after treatment were higher than those before treatment in the two groups(P<0.01). After treatment, the increased levels of SS and AVP were higher in the moxibustion group than in the Western medicine group (P<0.01).
CONCLUSION: Moxibustion is effective in improving the clinical symptom scores and regulating the levels of neuropeptides associated with learning and memory in VaD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619139     DOI: 10.3736/jcim20100706

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  6 in total

1.  Indirect moxibustion (CV4 and CV8) ameliorates chronic fatigue: a randomized, double-blind, controlled study.

Authors:  Hyeong Geug Kim; Sa Ra Yoo; Hye Jung Park; Chang-Gue Son
Journal:  J Altern Complement Med       Date:  2012-07-03       Impact factor: 2.579

2.  Effectiveness and safety of moxibustion for vascular dementia: A systematic review and meta-analysis.

Authors:  Xinqi Jiang; Tao Lu; Yihang Dong; Jiaru Shi; Mengyao Duan; Xiaoqing Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

Review 3.  The Efficacy and Underlying Mechanism of Moxibustion in Preventing Cognitive Impairment: A Systematic Review of Animal Studies.

Authors:  Seon Choe; Mudan Cai; Ui Min Jerng; Jun-Hwan Lee
Journal:  Exp Neurobiol       Date:  2018-02-13       Impact factor: 3.261

Review 4.  Moxibustion for cognitive impairment: a systematic review and meta-analysis of animal studies.

Authors:  Sungmin Aum; Seon Choe; Mudan Cai; Ui Min Jerng; Jun-Hwan Lee
Journal:  Integr Med Res       Date:  2020-10-14

5.  srBERT: automatic article classification model for systematic review using BERT.

Authors:  Sungmin Aum; Seon Choe
Journal:  Syst Rev       Date:  2021-10-30

6.  Effect of Moxibustion Treatment on Degree Centrality in Patients With Mild Cognitive Impairment: A Resting-State Functional Magnetic Resonance Imaging Study.

Authors:  Ke Xu; Yichen Wei; Chengxiang Liu; Lihua Zhao; Bowen Geng; Wei Mai; Shuming Zhang; Lingyan Liang; Xiao Zeng; Demao Deng; Peng Liu
Journal:  Front Hum Neurosci       Date:  2022-08-02       Impact factor: 3.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.